AzTrials
AzTrials

Cystic FibrosisMUCO-FIBRONCT02342964

Comparison of Non-invasive Measurement Methods of Hepatic Fibrosis in Cystic Fibrosis

A study testing Measure of hepatic elasticity in people with Cystic Fibrosis, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Non-invasive methods of the quantification of fibrosis may help to assess the development of fibrosis at a specific moment of the evolution of the disease, in the order to decide the initiation of treatment with ursodeoxycholic acid which may slow the progression to hepatic cirrhosis: FibroTest, The ultrasound impulse… Read more about this study

Who is it for?
Ages 6 to 18 years
Conditions the study is for
Cystic Fibrosis
What is being tested?
Measure of hepatic elasticity
Could I receive a placebo?
No, everyone receives an active treatment
How many people
56 participants
Where
1 siteFrance
Study dates
8 Jan 2015to 24 Jan 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Children with cystic fibrosis aged 6-18 years. The diagnosis of cystic fibrosis will be based on testing the abnormal sweat (> 60 mEq / L of chloride sweat) and / or on the presence of two pathogen mutations of CFTR.
  • Written consent of parents or holders of parental rights.
  • Affiliated or benefiting from a national social insurance

Who cannot join

  • Presence of another disease associated with cystic fibrosis that may be responsible for a chronic hepatic disease such as deficiency of alpha-1antitrypsine ZZ genotype or chronic infection by virus B or C.
  • Child grafted
  • Actual febrile pulmonary infection that can change the value of Fibrotest
  • Important peri-hepatic ascites preventing the elasticity measurements by Fibroscan®
  • Severe respiratory insufficient preventing attainment of Magnetic Resonance Imagery

Trial locations and contacts

1 site in 1 country.

France1 site
  • Hôpital Necker

    Paris, 75015

Other trials in France

About this study

Official title: Comparative Study of Different Non-invasive Measurement Methods of Hepatic Fibrosis in Cystic Fibrosis

Non-invasive methods of the quantification of fibrosis may help to assess the development of fibrosis at a specific moment of the evolution of the disease, in the order to decide the initiation of treatment with ursodeoxycholic acid which may slow the progression to hepatic cirrhosis:

  • FibroTest,
  • The ultrasound impulse elastography, Fibroscan (FS)
  • Ultrasound Elastography by ShearWave (SWE)
  • Magnetic resonance elastography (MRE). The purpose of this study is to assess the contribution of these methods in the diagnosis of hepatic fibrosis during the evolution of the cystic fibrosis.
Read the detailed description

The incidence of hepatobiliary disease in cystic fibrosis in the first 10 years of life is 2.5 to 1.8 / 100 patient-years, significantly decreasing during the second decade; generally 30-40% of children develop hepatic disease before 12 years. However, the hepatobiliary damage varies in its clinical and histological expression. The typical histological appearance of the liver is the focal biliary cirrhosis (or fibrosis) characterized by a heterogeneous distribution of portal fibrosis in the liver.

Complications of cirrhosis are responsible for 2.5% of deaths in patients with cystic fibrosis and represent the second cause of death after lung disease if we exclude deaths secondary to lung transplantation.

The diagnosis of hepatic disease at an early stage of development and the assessment of the progression of fibrosis are so difficult in the absence of sensitive and specific non-invasive diagnostic tests.

Non-invasive assessment of hepatic fibrosis is an important topic of study in recent years, because of the emergence of biological methods and quantitative elastography methods using ultrasound or Magnetic Resonance Imagery (MRI) and allowing quantification of the hepatic elasticity, which is assumed to be a reflection of fibrosis. The advantages of these methods are numerous:

  • The assessment of wider hepatic parenchyma then hepatic biopsy, allowing overcome the sampling bias
  • Painless and non-invasive methods for the patient
  • Simple to make
  • Do not require hospitalization and can be performed as outpatient
  • Immediately known results
  • Can be repeated as often as necessary during the patient's follow-up
  • Lower cost, morbidity and mortality compared to hepatic biopsy. Several non-invasive methods of fibrosis diagnosis have been studied in adults primarily for viral diseases and helped to limit the indications of hepatic biopsy. However, no method is now validated for the early diagnosis of hepatic disease and monitoring of children with cystic fibrosis.

The main objective of the study is to assess the contribution of FibroTest, the ultrasound impulse elastography, Fibroscan (FS), the ultrasound elastography by ShearWave (SWE) and Magnetic Resonance Elastography (MRE ) in the diagnosis of hepatic fibrosis in cystic fibrosis.

The secondary objectives are following :

  • To study the correlations between the fibrosis quantitative results obtained through the four techniques of measurement and the matches between the results of four techniques using the standards available at t0 and after a year (t1).
  • Study the correlations between clinical, biological and ultrasound endpoints of hepatic disease and various non-invasive measurement methods of fibrosis.
  • Evaluate the area under the ROC curve of the different tests and the diagnostic performance tests using analytical methods without gold standard by classifying the children into two groups: the presence of advanced fibrosis (stages F2 to F4 ) or not (F0 and F1 stages), contracting by a committee according to the results of any biopsy, clinical, laboratory and ultrasound endpoints independent on the tests.
Conditions
Cystic Fibrosis
Being tested
Measure of hepatic elasticity
Keywords
Cystic fibrosis, hepatic fibrosis, hepatic cirrhosis, non-invasive methods of measurement, hepatic elasticity
Medical subject headings
Cystic Fibrosis, Liver Cirrhosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Measure of hepatic elasticityOther

    Measure of hepatic elasticity by four non-invasive methods:

    Fibroscan, Fibrotest, SWE, MRE.

Study groups in NCT02342964
Study groupRoleWhat they receive
MUCO-FIBROOtherMeasures of hepatic elasticity
Receives: Other: Measure of hepatic elasticity

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measure of hepatic elasticity by Fibro Test

    The value of hepatic elasticity measured by each of the tests performed on the same day in the same patient

    Measured: Day 0

  2. Measure of hepatic elasticity by the ultrasound impulse elastography, Fibroscan (FS)

    The value of hepatic elasticity measured by each of the tests performed on the same day in the same patient.

    Measured: Month 12

Secondary outcomes (2)
  1. Measure of hepatic elasticity by Ultrasound Elastography by ShearWave (SWE):

    The existence of advanced hepatic fibrosis (stages F2 to F4) will be defined by the presence of clinical, and / or biological and / or ultrasound abnormalities, defining two groups of children (F + :children with advanced fibrosis, F-: children with little or no fibrosis

    Measured: Day 0

  2. Measure of hepatic elasticity by Magnetic resonance elastography (MRE):

    The existence of advanced hepatic fibrosis (stages F2 to F4) will be defined by the presence of clinical, and / or biological and / or ultrasound abnormalities, defining two groups of children (F + :children with advanced fibrosis, F-: children with little or no fibrosis

    Measured: Month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2015 (estimated)
  2. Study start8 Jan 2015
  3. Primary completionJan 2019
  4. Study completion24 Jan 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
56 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02342964
Sponsor's protocol ID
RCB-2013-A01579-36
Acronym
MUCO-FIBRO
Status last verified
Nov 2025
First submitted
6 Nov 2014
Last updated
20 Nov 2025
Results posted
No
Data monitoring committee
No

Publications

  • Dana J, Girard M, Franchi-Abella S, Berteloot L, Benoit-Cherifi M, Imbert-Bismut F, Sermet-Gaudelus I, Debray D. Comparison of Transient Elastography, ShearWave Elastography, Magnetic Resonance Elastography and FibroTest as routine diagnostic markers for assessing liver fibrosis in children with Cystic Fibrosis. Clin Res Hepatol Gastroenterol. 2022 Mar;46(3):101855. doi: 10.1016/j.clinre.2021.101855. Epub 2021 Dec 20.

    PubMed 34933150

Questions about this trial

What is this clinical trial studying?

A study testing Measure of hepatic elasticity in people with Cystic Fibrosis, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measure of hepatic elasticity by Fibro Test (time frame: Day 0). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02342964, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in